Global House Dust Mite Allergy Market
$7 Bn House Dust Mite Allergy Global Market Opportunities and Strategies to 2033 - Innovative AI-Powered Allergy Testing Revolutionizes Market Dynamics
June 26, 2024 06:22 ET | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "House Dust Mite Allergy Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global...
22157.jpg
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials
June 20, 2024 06:59 ET | Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
Tevogen Logo Notified.png
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
June 18, 2024 15:17 ET | Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
finacialnews-logo-final-01 (2).png
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET | FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Tevogen Logo Notified.png
Tevogen Bio Set to Join Russell 3000® Index
June 12, 2024 15:45 ET | Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
Tevogen Logo Notified.png
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 11, 2024 15:30 ET | Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
22157.jpg
Trispecific Antibodies Set to Transform the Future of Immunotherapy: Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
June 07, 2024 02:59 ET | Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The blueprint...
Tevogen Logo Notified.png
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 06, 2024 15:52 ET | Tevogen Bio Inc
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
barinthuslogo.jpg
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET | Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Vaccinex logo
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
June 06, 2024 08:30 ET | Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.